Skip to content
Peptidepedia

How to Use Retatrutide: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration

Retatrutide is administered via subcutaneous injection once weekly. In clinical trials, participants self-administered injections following standard subcutaneous injection protocols.

Injection sites: Common subcutaneous injection sites include the abdomen (avoiding the navel area), front of thighs, or upper arms. Rotation of injection sites is recommended to prevent lipodystrophy.

Timing: Retatrutide can be administered at any time of day, with or without meals. Consistency in weekly timing is recommended.

Injection technique: Standard subcutaneous injection protocols apply: clean the injection site with alcohol, pinch the skin, insert the needle at a 45 to 90 degree angle, inject slowly, and apply gentle pressure after withdrawal.

Reconstitution, Storage & Prep

Lyophilized (powder) form storage:

  • Store at -20°C for long-term preservation
  • Protect from light
  • Stable at 2-8°C (refrigerator) for shorter periods

Reconstitution protocol:

  1. Allow the vial to reach room temperature
  2. Draw bacteriostatic water using a sterile syringe (typically 2 mL for a 10 mg vial)
  3. Inject the diluent slowly down the vial wall to avoid foaming
  4. Gently swirl or roll the vial until the powder fully dissolves; do not shake vigorously
  5. Inspect for complete dissolution and absence of particulates

Reconstituted solution storage:

  • Store at 2-8°C (refrigerator)
  • Use within 28-30 days of reconstitution
  • Protect from light
  • Do not freeze the reconstituted solution

Frequently Asked Questions

Gastrointestinal effects, including nausea, diarrhea, vomiting, and constipation, are most common. These typically occur during dose escalation, are mild to moderate, and often improve with continued use. In Phase 3 (TRIUMPH-4), dysesthesia (abnormal skin sensation) emerged as a new safety signal at 20.9% incidence with the 12 mg dose.

Retatrutide is administered as a once-weekly subcutaneous injection. Clinical trials used dose escalation starting at 2 to 4 mg weekly, increasing every 4 weeks to maintenance doses of 4 to 12 mg.

Clinical trials have demonstrated significant improvements in glycemic control in participants with type 2 diabetes, including HbA1c reductions and reversion of prediabetes to normoglycemia. However, it is not yet approved for any indication.

Reconstituted retatrutide should be refrigerated at 2-8°C, protected from light, and used within 28-30 days. Do not freeze the reconstituted solution.

Dysesthesia is an abnormal sense of touch where normal sensations feel unusual, tingly, or uncomfortable. In the Phase 3 TRIUMPH-4 trial, dysesthesia occurred in 20.9% of participants on the 12 mg dose compared with 0.7% on placebo. It did not appear in Phase 2 trials and is thought to be caused by glucagon receptor activation in cutaneous sensory neurons — a mechanism unique to retatrutide among incretin-class drugs. Cases were generally mild and rarely led to discontinuation.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.
  3. Eli Lilly. What to know about retatrutide.
  4. Lilly's triple G agonist boasts 28.7% weight loss in Phase III trial. Clinical Trials Arena. 2025.
  5. Lilly's obesity triple pulls off 29% weight loss in trial. Pharmaphorum. 2025.
  6. Effects of retatrutide on body composition in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2025.
  7. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist. PMC. 2024.
  8. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatohepatitis. Nature Medicine. 2024.
  9. The power of three: Retatrutide's role in modern obesity management. European Journal of Pharmacology. 2024.
  10. Retatrutide for Weight Loss: Availability, Dosage, and More. GoodRx. 2025.
  11. Eli Lilly. Lilly's retatrutide demonstrates significant improvements in blood sugar control and weight loss in adults with type 2 diabetes (TRANSCEND-T2D-1). Press release, March 2026.
  12. Marathe CS, et al. Retatrutide suppresses tumor growth in preclinical models of pancreatic and lung cancer. npj Metabolic Health and Disease. 2025.
  13. Retatrutide — A Game Changer in Obesity Pharmacotherapy: A Comprehensive Review. Biomolecules. 2025.
  14. Eli Lilly. Lilly's triple agonist retatrutide delivered weight loss averaging 28.7% in Phase 3 TRIUMPH-4 trial. Press release, December 2025.
  15. WADA Prohibited List 2026. World Anti-Doping Agency.
←Read the full Retatrutide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”